A greater than expected increase in April producer prices weighed the markets down to a lower open with the Dow falling 55 points to 16,659. Nasdaq lost 10 points to 4,119.

On the upside 

Pernix Therapeutics Holdings (Nasdaq: PTX) will acquire the U.S. rights to GlaxoSmithKline’s (NYSE: GSK) migraine treatment Treximet.

Arotech (Nasdaq: ARTX) reported sharply higher first quarter earnings that nearly doubled to surpass analyst expectations by a wide margin.

Celldex (Nasdaq: CLDX) will collaborate with Bristol-Myers Squibb (NYSE: BMY) to conduct a clinical trial to evaluate the effectiveness of combining nivolumab and varlilumab in treating cancer.

On the downside 

USA Compression Partners (NYSE: USAC) priced its offering of 6.6 million common units at the discounted price of $25.59 per common unit.

Quantum Fuel Systems Technologies (Nasdaq: QTWW) reported a wider than expected loss for the first quarter.

First quarter earnings plunged for URS (NYSE: URS) to miss expectations.

In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on the NYSE and by nearly 5 to 3 on Nasdaq. The broader S&P 500 slipped 2 points to 1895. Bitcoin added  $3.02 or 0.69% to $438.96.